New funding boosts head and neck cancer research

UCL has appointed a new Clinical Senior Lecturer to lead the development of clinical trials relating to head and neck cancer, which account for six per cent of all cancers in the UK. From September 2009, Martin Forster will join the UCL Cancer Institute to lead the development of new early-phase clinical trials for these malignancies. UCL researchers at the Cancer Institute are already studying the genetic make-up of the complex tumours that characterise head and neck cancer. A phase I clinical trial is also soon to open for patients with recurrent or advanced head and neck cancer at the new Clinical Research Facility at UCL Hospital. It is hoped that this research will have an impact on the future management and outcome for these rarely profiled cancers. Head and neck cancers include those of the tongue, throat, tonsils and larynx. They are mainly associated with smoking, but a link has recently been identified to the same virus which causes cervical cancer (i.e.
account creation

TO READ THIS ARTICLE, CREATE YOUR ACCOUNT

And extend your reading, free of charge and with no commitment.

Register


Login

Your Benefits

  • Access to all content
  • Receive newsmails for news and jobs
  • Post ads

myScience